Last reviewed · How we verify

fan li — Portfolio Competitive Intelligence Brief

fan li pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abivax S.A. · 1 shared drug class
  2. Akorn, Inc. · 1 shared drug class
  3. Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
  4. Health Research, Inc. · 1 shared drug class
  5. Imperial College London · 1 shared drug class
  6. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  7. Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 shared drug class
  8. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for fan li:

Cite this brief

Drug Landscape (2026). fan li — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fan-li. Accessed 2026-05-15.

Related